Navigation Links
Omeros Announces Positive Clinical Results of OMS201 in Patients Undergoing Ureteroscopy
Date:12/29/2010

SEATTLE, Dec. 29, 2010 /PRNewswire-FirstCall/ -- Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced results from the Phase 1/2 clinical trial of OMS201, the Company's urological PharmacoSurgery™ product candidate. OMS201 is a proprietary combination of an anti-inflammatory agent and a smooth muscle relaxant, each with well-known safety and pharmacologic profiles.

Based on the successfully completed Phase 1 trial of a lower concentration of OMS201, this Phase 1/2 study was designed to evaluate the safety and systemic absorption of two sequentially higher concentrations of OMS201 added to standard irrigation solution and delivered to patients undergoing ureteroscopy for removal of ureteral or renal stones. This multicenter, double-blind, placebo-controlled study also explored potential efficacy endpoints but was not powered to assess efficacy. Based on an interim analysis of the pharmacokinetic data, which demonstrated low maximal systemic absorption of the active ingredients, trial enrollment was truncated from the originally planned 36 patients to a total of 24 patients.

OMS201 was safe and well tolerated in this study. The incidence of adverse events was similar in the two OMS201-concentration arms and the group receiving vehicle. No adverse events were considered treatment-related by investigators. There were no deaths or discontinuations for adverse events. Only one serious adverse event was reported, which occurred in a vehicle-treated patient.

"We are pleased with the results of this trial, which demonstrated an absence of side-effects even at a concentration of OMS201 ten times higher than that examined in our earlier Phase 1 clinical study," said Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. "These data will help us to design subsequent trials evaluating the efficacy and safety of OMS201 in patients undergoing urologic procedures."

About Omeros Corporation

Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. The Company's most clinically advanced product candidates are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has five ongoing clinical development programs, including four from its PharmacoSurgery™ platform, the most advanced of which is in a Phase 3 clinical program, and one from its Addiction program. Omeros may also have the near-term capability, through its GPCR program, to add wholly new drug targets to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of antibody and small-molecule preclinical programs targeting inflammation and central nervous system disorders.

Forward-looking Statements

This press release contains forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, which are subject to the "safe harbor" created by those sections. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release and include the Company's ability to design subsequent trials evaluating the efficacy and safety of OMS201 in patients undergoing urologic procedures. Omeros' actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors described under the heading "Risk Factors" in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 4, 2010. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the Company assumes no obligation to update these forward-looking statements publicly, even if new information becomes available in the future.


'/>"/>
SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Omeros to Host Conference Call Monday, October 25 at 4:00 p.m. ET To Provide Corporate Update
2. Omeros to Present at the BioCentury NewsMakers Conference
3. Omeros Enrolls First Patient in Phase 2b Clinical Trial Evaluating OMS302 in Patients Undergoing Cataract Surgery
4. Omeros Successfully Unlocks Orphan GPCRs
5. Omeros Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders
6. Omeros Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery
7. Omeros Announces National Institute on Drug Abuses Support for Phase 2 Clinical Study in Addiction Program
8. Daniel K. Spiegelman Elected to Board of Directors of Omeros
9. Omeros Corporation to Host Third Quarter 2009 Financial Results Conference Call on November 19
10. Omeros Prices Initial Public Offering of Common Stock at $10.00 Per Share
11. Omeros Receives $3.1 Million Milestone Payment from The Stanley Medical Research Institute for Schizophrenia Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/7/2017)... , June 7, 2017  Novavax, Inc., (Nasdaq: ... two Phase 2 trials of its RSV F protein recombinant ... bearing age have been published in the journal ... been shared in prior scientific conferences). The Company previously announced ... 2014. Novavax is developing the RSV F Vaccine with the ...
(Date:6/5/2017)... -- The Cincinnati location of Diplomat ... DPLO), has been awarded a Top Workplaces 2017 ... are based on an employee survey administered by WorkplaceDynamics, LLC, ... The survey measures several aspects of workplace culture, including alignment, ... ...
(Date:6/3/2017)... , June 3, 2017  Eli Lilly ... announced that results from the Phase 3 MONARCH ... (CDK)4 & 6 inhibitor, in combination with fulvestrant, ... with fulvestrant alone in women with hormone-receptor-positive (HR+), ... breast cancer who have relapsed or progressed after ...
Breaking Medicine Technology:
(Date:6/26/2017)... ... June 26, 2017 , ... If the devil is in ... red these days. According to recent estimates, 75 – 80% of the medical ... Some studies point to Electronic Health Records (EHR) with automated features designed to ...
(Date:6/25/2017)... CA (PRWEB) , ... June 24, 2017 , ... Create a feel-good lyric music video ... above footage and sound in the timeline and write in the lyrics to any song. ... flying back out. Each line of the text can be added modularly for optimal control. ...
(Date:6/25/2017)... , ... June 25, 2017 , ... With a heatwave currently bearing down on Northern ... out at the pool. Being swimsuit ready is easy with laser hair removal. , ... again can be a burdensome routine when all you want to do is get out, ...
(Date:6/24/2017)... ... June 24, 2017 , ... Dr. ... 217 Portion Road in Lake Ronkonkoma, Dental365 offers patients high-quality and affordable routine ... visits to the dentist fit into their patients’ busy lifestyles. Dental365 also gladly ...
(Date:6/23/2017)... ... June 23, 2017 , ... "The Better Care Reconciliation ... significant harm to people with all chronic conditions, including mental illnesses, while increasing ... place the Affordable Care Act (ACA) requirement that insurers cover pre-existing conditions, it ...
Breaking Medicine News(10 mins):